Results (
Thai) 1:
[Copy]Copied!
9.14.Randomisation ProceduresA dynamic permuted block system to provide balancing within clinic sites will be used to randomize women in approximately equal numbers to receive either the PI-based or NRTI-based regimen. Randomization will be assigned by calling the Data Management Centre in Gaborone, in the same manner as was successfully performed for 1200 women in the Mashi Study.The Study staff will fill out the Study Eligibility Checklist for each participant agreeing to be in the study. The site personnel then communicate this information to the Data Centre in Gaborone, where each question on the Checklist will be reviewed. If eligible, the Data Centre will assign the subject a study ID (SID) randomisation number, and a BHP identification number (BHP ID) to replace the screening Participant ID or PID as the key identifier on all subsequent study forms. The Data Centre will provide these identification numbers to the site during the phone call, and follow up with a written confirmation of the randomization arm (for those eligible to be randomized). The BHP ID and SID, and HAART regimen (“NVP/CBV” for those not randomized, “TZV” or “Kaletra/CBV” for those randomized) should be immediately written onto the participant’s obstetrical record adjacent to the screening PID number in the “Admission” section and on documents kept at the Study clinic. Participants will be informed of their HAART regimen at this time, further educated about it, and questions will be answered.All randomization assignments will be made based upon computer-generated lists. Participants will not be able to choose the group to which they will be assigned. Participants who are randomised but do not start study drug continue follow-up during the required duration of study observation unless they refuse further follow-up, are lost to follow-up, die, or the study closes.
Being translated, please wait..